Skip to main content

Bosulif News

FDA Approves Bosutinib for Pediatric Patients with Chronic Myelogenous Leukemia

September 27, 2023 – On September 26, 2023, the Food and Drug Administration approved bosutinib (Bosulif, Pfizer) for pediatric patients 1 year of age and older with chronic phase (CP) Ph+ chronic...

FDA Approves Pfizer’s Bosulif (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)

December 19, 2017 – Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indication for Bosulif...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Chronic Myelogenous Leukemia (CML)

Bosulif patient information at Drugs.com